Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.

Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T.

J Infect Dis. 2011 Dec 15;204(12):1951-9. doi: 10.1093/infdis/jir658. Epub 2011 Oct 21.

2.

[Trends in tuberculosis treatment duration].

Veziris N, Aubry A, Truffot-Pernot C.

Presse Med. 2006 Nov;35(11 Pt 2):1758-64. Review. French.

PMID:
17086138
3.

Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.

Chakraborty S, Rhee KY.

Cold Spring Harb Perspect Med. 2015 Apr 15;5(8):a021147. doi: 10.1101/cshperspect.a021147. Review.

PMID:
25877396
4.

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.

Somoskovi A, Parsons LM, Salfinger M.

Respir Res. 2001;2(3):164-8. Epub 2001 Apr 5. Review.

5.

[Resistant tuberculosis: a molecular review].

Rossetti ML, Valim AR, Silva MS, Rodrigues VS.

Rev Saude Publica. 2002 Aug;36(4):525-32. Review. Portuguese.

6.

A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.

Pasipanodya JG, Gumbo T.

Curr Opin Pharmacol. 2011 Oct;11(5):457-63. doi: 10.1016/j.coph.2011.07.001. Epub 2011 Jul 30. Review.

7.

[Molecular mechanisms of multidrug resistance in Mycobacterium tuberculosis].

Taniguchi H.

J UOEH. 2000 Sep 1;22(3):269-82. Review. Japanese.

PMID:
11019393
8.

[Emerging and drug-resistant infectious diseases--multi-drug resistant tuberculosis].

Yano I.

Nihon Naika Gakkai Zasshi. 1997 Nov 10;86(11):2095-102. Review. Japanese. No abstract available.

PMID:
9480316
Items per page

Supplemental Content

Write to the Help Desk